[go: up one dir, main page]

WO2017024317A3 - Procédés pour induire la dégradation de protéine ciblée par des molécules bifonctionnelles - Google Patents

Procédés pour induire la dégradation de protéine ciblée par des molécules bifonctionnelles Download PDF

Info

Publication number
WO2017024317A3
WO2017024317A3 PCT/US2016/046087 US2016046087W WO2017024317A3 WO 2017024317 A3 WO2017024317 A3 WO 2017024317A3 US 2016046087 W US2016046087 W US 2016046087W WO 2017024317 A3 WO2017024317 A3 WO 2017024317A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
protein degradation
targeted protein
bifunctional molecules
induce targeted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/046087
Other languages
English (en)
Other versions
WO2017024317A2 (fr
Inventor
James Bradner
Dennis BUCKLEY
Georg Winter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of WO2017024317A2 publication Critical patent/WO2017024317A2/fr
Publication of WO2017024317A3 publication Critical patent/WO2017024317A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des composés bifonctionnels qui servent de fragments induisant la dégradation de protéine. La présente invention concerne également des acides nucléiques, des polypeptides, des cellules, et des procédés pour la dégradation ciblée, hautement régulée, de protéines par utilisation des composés bifonctionnels.
PCT/US2016/046087 2015-08-06 2016-08-08 Procédés pour induire la dégradation de protéine ciblée par des molécules bifonctionnelles Ceased WO2017024317A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562202076P 2015-08-06 2015-08-06
US62/202,076 2015-08-06

Publications (2)

Publication Number Publication Date
WO2017024317A2 WO2017024317A2 (fr) 2017-02-09
WO2017024317A3 true WO2017024317A3 (fr) 2017-04-27

Family

ID=56990946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/046087 Ceased WO2017024317A2 (fr) 2015-08-06 2016-08-08 Procédés pour induire la dégradation de protéine ciblée par des molécules bifonctionnelles

Country Status (1)

Country Link
WO (1) WO2017024317A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
US12358925B2 (en) 2019-02-02 2025-07-15 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Targeted ubiquitination degradation BRD4 protein compound, preparation method therefor and application thereof

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3082797A4 (fr) 2013-12-18 2017-12-13 The California Institute for Biomedical Research Agents thérapeutiques modifiés, conjugués lipide-peptide agrafés, et compositions les comprenant
WO2016105518A1 (fr) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
KR102564925B1 (ko) * 2015-01-20 2023-08-07 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2017007612A1 (fr) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles
EP3337476A4 (fr) 2015-08-19 2019-09-04 Arvinas, Inc. Composés et procédés pour la dégradation ciblée de protéines contenant un bromodomaine
EP3445357B1 (fr) 2016-04-22 2021-05-26 Dana-Farber Cancer Institute, Inc. Molécules bifonctionnelles pour la dégradation du egfr et méthodes d'utilisation
WO2017197055A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP3454862B1 (fr) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2018064589A1 (fr) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Dégradation ciblée de protéines à l'aide d'une ubiquitine ligase e3 mutante
EP3532464A4 (fr) 2016-10-28 2020-07-08 Icahn School of Medicine at Mount Sinai Compositions et procédés pour le traitement du cancer à médiation par l'ezh2
CN117510491A (zh) 2016-12-23 2024-02-06 阿尔维纳斯运营股份有限公司 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CN111315735B (zh) 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
EP3679026A1 (fr) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
EP3679028A1 (fr) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydroquinolinones
WO2019084026A1 (fr) 2017-10-24 2019-05-02 Genentech, Inc. Composés (4-hydroxypyrrolidin-2-yl)-hétérocycliques et leurs procédés d'utilisation
EP3710002A4 (fr) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. Agents de dégradation et dégrons pour dégradation protéique ciblée
EP3755690A4 (fr) * 2018-02-20 2021-10-27 Dana-Farber Cancer Institute, Inc. Inhibiteurs d'egfr et leurs procédés d'utilisation
US20200377477A1 (en) * 2018-02-20 2020-12-03 Dana-Farber Cancer Institute, Inc. Degraders of egfr and methods of use thereof
JP2021514012A (ja) * 2018-02-20 2021-06-03 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｅｇｆｒの分解誘導剤およびその使用法
WO2019165229A1 (fr) * 2018-02-23 2019-08-29 Dana-Farber Cancer Institute, Inc. Petites molécules permettant d'induire une dégradation sélective de protéines et utilisations associées
WO2019191112A1 (fr) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Liants de céréblon pour la dégradation d'ikaros
WO2019204354A1 (fr) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Composés spirocycliques
MX2020011183A (es) 2018-04-23 2020-11-12 Celgene Corp Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
EP3578561A1 (fr) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spirocomposés
WO2019238886A1 (fr) 2018-06-13 2019-12-19 University Of Dundee Molécules bifonctionnelles pour le ciblage de l'usp14
EP3807272A1 (fr) 2018-06-13 2021-04-21 Amphista Therapeutics Ltd Molécules bifonctionnelles pour cibler rpn11
CA3103205A1 (fr) 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Molecules bifonctionnelles pour cibler l'uchl5
CA3104298A1 (fr) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Composes de degradation/desintegration de la proteine 5 a domaine de repetition wd40 (wdr5) et methodes d'utilisation
US20230070613A1 (en) * 2018-07-05 2023-03-09 Icahn School Of Medicine At Mount Sinai Protein tyrosine kinase 6 (ptk6) degradation / disruption compounds and methods of use
EP3817822A4 (fr) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. Agents de dégradation de protéines et leurs utilisations
US20210324357A1 (en) * 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
CN112912376A (zh) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
CN111018857B (zh) * 2018-10-09 2023-06-02 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
US11691984B2 (en) 2018-10-12 2023-07-04 The Scripps Research Institute Compounds and methods for DCAF-mediated protein degradation
CA3119343C (fr) 2018-11-13 2024-01-16 Biotheryx, Inc. Isoindolinones substituees
CN120698985A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
AU2020205952A1 (en) 2019-01-07 2021-06-17 Dana-Farber Cancer Institute, Inc Small molecule degraders of FKBP12 via recruitment of Von Hippel-Lindau E3 ubiquitin ligase (VHL) E3 ubiquitin ligase, and uses in dTAG systems
WO2020160198A1 (fr) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Composés et leurs utilisations
EP3917529A4 (fr) 2019-01-29 2022-11-02 Foghorn Therapeutics Inc. Composés et leurs utilisations
AU2020218367A1 (en) * 2019-02-08 2021-08-12 University Of Florida Research Foundation, Incorporated Therapeutic agents and methods of treatment
US12233356B2 (en) 2019-03-21 2025-02-25 Lonza Sales Ag Process for preparing extracellular vesicles
JP2022525924A (ja) 2019-03-21 2022-05-20 コディアック バイオサイエンシーズ， インコーポレイテッド 細胞外小胞コンジュゲート及びその使用
WO2020200291A1 (fr) * 2019-04-02 2020-10-08 Cullgen (Shanghai) , Inc. Composés et méthodes de traitement de cancers
EA202192738A1 (ru) 2019-04-12 2022-03-17 С4 Терапьютикс, Инк. Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
CA3137916A1 (fr) 2019-05-06 2020-11-12 Ichan School Of Medicine At Mount Sinai Composes heterobifonctionnels en tant qu'agents de degradation de hpk1
AR119057A1 (es) * 2019-05-31 2021-11-17 Celgene Corp Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
CN119954801A (zh) 2019-07-17 2025-05-09 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法
CN119019369A (zh) 2019-10-17 2024-11-26 阿尔维纳斯运营股份有限公司 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子
CN114901277B (zh) 2019-12-20 2024-05-17 C4医药公司 用于egfr降解的异吲哚啉酮和吲唑化合物
CA3162502A1 (fr) 2019-12-23 2021-07-01 Yi Zhang Agents de degradation de smarca et leurs utilisations
US12441722B2 (en) 2020-01-15 2025-10-14 University Of Florida Research Foundation, Incorporated Therapeutic agents and methods of treatment
MX2022010952A (es) 2020-03-05 2022-10-07 C4 Therapeutics Inc Compuestos para la degradacion dirigida de brd9.
WO2021222138A1 (fr) * 2020-04-27 2021-11-04 Development Center For Biotechnology Composés pour la dégradation de la protéine ras mutante
WO2021237100A1 (fr) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Procédés d'administration ciblée de vésicules extracellulaires dans le poumon
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
JP2023539663A (ja) 2020-08-28 2023-09-15 アルビナス・オペレーションズ・インコーポレイテッド 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
US20240241020A1 (en) 2020-09-23 2024-07-18 Lonza Sales Ag Process for preparing extracellular vesicles
CN116323570B (zh) * 2020-09-30 2025-02-11 上海睿跃生物科技有限公司 治疗疾病的化合物和方法
WO2022078350A1 (fr) * 2020-10-14 2022-04-21 Ranok Therapeutics (Hangzhou) Co. Ltd. Méthodes et compositions pour la dégradation ciblée de protéines
TW202237095A (zh) 2020-12-03 2022-10-01 德商艾斯巴赫生物有限公司 Ａｌｃ１抑制劑及與ｐａｒｐｉ之協同性
US20250109138A1 (en) * 2020-12-09 2025-04-03 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
MX2023008296A (es) 2021-01-13 2023-09-29 Monte Rosa Therapeutics Inc Compuestos de isoindolinona.
WO2022221673A1 (fr) 2021-04-16 2022-10-20 Arvinas Operations, Inc. Modulateurs de protéolyse bcl6 et procédés d'utilisation associés
AU2022290851A1 (en) 2021-06-08 2023-11-23 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant braf
JP7685781B2 (ja) * 2021-06-08 2025-05-30 ハンチョウ グルビオ ファーマシューティカル カンパニー，リミティド イソインドリノン化合物およびその用途
IL309067A (en) 2021-06-09 2024-02-01 Scripps Research Inst Long-acting dual gip/glp-1 peptide conjugates and methods of use
WO2023283130A1 (fr) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Dérivés d'isoquinoléine en tant que modulateurs d'egfr mutants et leurs utilisations
JP7744061B2 (ja) * 2021-07-30 2025-09-25 ヒノバ ファーマシューティカルズ インコーポレイテッド 二官能性キメラ複素環式化合物及びアンドロゲン受容体分解剤としての使用
EP4426687A4 (fr) * 2021-11-04 2025-12-10 Brigham & Womens Hospital Inc Molécules de dégron dirigées et leurs applications
WO2023172889A1 (fr) * 2022-03-07 2023-09-14 The University Of North Carolina At Chapel Hill Utilisation de modificateurs épigénétiques chimiques pour moduler l'expression génique
CN119365198A (zh) 2022-05-02 2025-01-24 艾斯巴赫生物有限公司 ALC1抑制剂的用途和与PARPi的协同作用
CA3249074A1 (fr) 2022-06-06 2023-12-14 C4 Therapeutics, Inc. Liants de céréblon de glutarimide à substitution bicyclique
US20250361284A1 (en) * 2022-06-13 2025-11-27 Julius-Maximilians-Universität Würzburg Transposase fusion proteins for use in cell and gene therapy
WO2024054591A1 (fr) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Composés de dégradation de fibrosarcome rapidement accéléré (raf) et procédés d'utilisation associés
WO2024081913A1 (fr) * 2022-10-14 2024-04-18 76Bio, Inc. Protéines de fusion bifonctionnelles à double spécificité pour dégradation médiée par l'ubiquitine
WO2024240078A1 (fr) * 2023-05-19 2024-11-28 The Chinese University Of Hong Kong Compositions et procédés associés au marquage de protéines
WO2025006783A2 (fr) 2023-06-30 2025-01-02 Merck Patent Gmbh Composés hétérobifonctionnels pour la dégradation de kras
WO2025006753A2 (fr) 2023-06-30 2025-01-02 Merck Patent Gmbh Composés hétérobifonctionnels pour la dégradation de la protéine kras

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029827A2 (fr) * 2001-10-01 2003-04-10 Bioimage A/S Methode amelioree permettant de detecter des interactions entre des constituants cellulaires presents dans des cellules vivantes intactes et d'extraire des informations quantitatives se rapportant auxdites interactions par nouvelle repartition de fluorescence
WO2014159312A2 (fr) * 2013-03-14 2014-10-02 University Of Florida Research Foundation, Incorporated Nouvelles agrégation et toxicité diminuées d'alpha-1 antitrypsine mutante à anticorps à chaîne unique
US20140335539A1 (en) * 2011-12-05 2014-11-13 Medical & Biological Laboratories Co., Ltd. Method for detecting protein-protein interaction

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
ATE141646T1 (de) 1986-04-09 1996-09-15 Genzyme Corp Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (fr) 1990-05-03 1991-11-14 Vical, Inc. Acheminement intracellulaire de substances biologiquement actives effectue a l'aide de complexes de lipides s'auto-assemblant
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6231600B1 (en) 1995-02-22 2001-05-15 Scimed Life Systems, Inc. Stents with hybrid coating for medical devices
US5837313A (en) 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
ZA9710342B (en) 1996-11-25 1998-06-10 Alza Corp Directional drug delivery stent and method of use.
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US5891507A (en) 1997-07-28 1999-04-06 Iowa-India Investments Company Limited Process for coating a surface of a metallic stent
US6153252A (en) 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
US6248127B1 (en) 1998-08-21 2001-06-19 Medtronic Ave, Inc. Thromboresistant coated medical device
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6203551B1 (en) 1999-10-04 2001-03-20 Advanced Cardiovascular Systems, Inc. Chamber for applying therapeutic substances to an implant device
US6251136B1 (en) 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US6517889B1 (en) 2001-11-26 2003-02-11 Swaminathan Jayaraman Process for coating a surface of a stent
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029827A2 (fr) * 2001-10-01 2003-04-10 Bioimage A/S Methode amelioree permettant de detecter des interactions entre des constituants cellulaires presents dans des cellules vivantes intactes et d'extraire des informations quantitatives se rapportant auxdites interactions par nouvelle repartition de fluorescence
US20140335539A1 (en) * 2011-12-05 2014-11-13 Medical & Biological Laboratories Co., Ltd. Method for detecting protein-protein interaction
WO2014159312A2 (fr) * 2013-03-14 2014-10-02 University Of Florida Research Foundation, Incorporated Nouvelles agrégation et toxicité diminuées d'alpha-1 antitrypsine mutante à anticorps à chaîne unique

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
G. E. WINTER ET AL: "Phthalimide conjugation as a strategy for in vivo target protein degradation", SCIENCE, vol. 348, no. 6241, 19 June 2015 (2015-06-19), pages 1376 - 1381, XP055328122, ISSN: 0036-8075, DOI: 10.1126/science.aab1433 *
JAN KRÖNKE ET AL: "Lenalidomide induces ubiquitination and degradation of CK1[alpha] in del(5q) MDS", NATURE, vol. 523, no. 7559, 9 July 2015 (2015-07-09), United Kingdom, pages 183 - 188, XP055336278, ISSN: 0028-0836, DOI: 10.1038/nature14610 *
M. SEKIGUCHI ET AL: "An evaluation tool for FKBP12-dependent and -independent mTOR inhibitors using a combination of FKBP-mTOR fusion protein, DSC and NMR", PROTEIN ENGINEERING, DESIGN AND SELECTION, vol. 24, no. 11, 6 September 2011 (2011-09-06), GB, pages 811 - 817, XP055336205, ISSN: 1741-0126, DOI: 10.1093/protein/gzr045 *
PHILIP P CHAMBERLAIN ET AL: "Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs", NATURE STRUCTURAL AND MOLECULAR BIOLOGY, vol. 21, no. 9, 10 August 2014 (2014-08-10), US, pages 803 - 809, XP055336279, ISSN: 1545-9993, DOI: 10.1038/nsmb.2874 *
ROBERS MATT ET AL.: "Fluorescent labeling of proteins in living cells using the FKBP12 (F36V) tag", CYTOMETRY. PART A : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR ANALYTICAL CYTOLOGY, vol. 75, no. 3, March 2009 (2009-03-01), pages 207 - 224, XP002762671, ISSN: 1552-4930 *
WANG T ET AL: "Specific Interaction of Type I Receptors of the TGF-beta Family with the Immunophilin FKBP-12", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, vol. 265, 29 July 1994 (1994-07-29), pages 674 - 676, XP002173914, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.7518616 *
WANG XIAO-SONG ET AL: "Characterization of KRAS rearrangements in metastatic prostate cancer", CANCER DISCOVERY,, vol. 1, no. 1, 1 June 2011 (2011-06-01), pages 35 - 43, XP009167682, ISSN: 2159-8290, DOI: 10.1158/2159-8274.CD-10-0022 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358925B2 (en) 2019-02-02 2025-07-15 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Targeted ubiquitination degradation BRD4 protein compound, preparation method therefor and application thereof
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof

Also Published As

Publication number Publication date
WO2017024317A2 (fr) 2017-02-09

Similar Documents

Publication Publication Date Title
WO2017024317A3 (fr) Procédés pour induire la dégradation de protéine ciblée par des molécules bifonctionnelles
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
EP3773727A4 (fr) Petites molécules bifonctionnelles pour cibler la dégradation sélective de protéines circulantes
WO2015109124A3 (fr) Agents immunomodulateurs
TWI799368B (zh) 抗ｔｌ１ａ抗原結合蛋白及相關核酸、表現載體、宿主細胞、醫藥組合物、方法及用途
WO2018081592A3 (fr) Compositions et procédés pour la production de composés
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
WO2016065349A8 (fr) Arn non codants courts régulateurs de protéines (sprrna) et procédés d'utilisation
EP3741849A3 (fr) Variantes de protéases et polynucléotides les codant
HK1258509A1 (zh) Gitr激动剂
WO2015196128A3 (fr) Molécules d'acide nucléique alternatives et leurs utilisations
WO2015196130A3 (fr) Molécules d'acide nucléique alternatives et leurs utilisations
MX383614B (es) Proteinas de union triespecificas y metodos de uso.
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
MX2021010668A (es) Proteinas de fusion de citoquinas.
WO2015112886A3 (fr) Protéines de liaison et leurs procédés d'utilisation
WO2016066756A3 (fr) Variants de protéase et polynucléotides les codant
WO2016066757A3 (fr) Variants de protéase et polynucléotides les codant
EP3604535A3 (fr) Procédés et compositions utilisables pour lutter contre les mauvaises herbes
WO2015089511A3 (fr) Molécules d'acides nucléiques modifiés et leurs utilisations
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
WO2016063026A3 (fr) Séquences de liaison sélectives pour la protéine nav
BR112017016897A2 (pt) cepas fúngicas e métodos de uso
WO2015160928A3 (fr) Récepteurs des lymphocytes t isolés et leurs procédés d'utilisation
WO2015161267A3 (fr) Anticorps monoclonaux humanisés et chimériques contre cd99

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16770585

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16770585

Country of ref document: EP

Kind code of ref document: A2